Company news
Soligenix, Inc. news in 2021
Soligenix, Inc.'s news releases, calls and decks from 2021, newest first.
Soligenix Announces Recent Accomplishments And Third Quarter 2021 Financial Results
November 11, 2021
Soligenix Granted Pediatric Investigational Plan Waiver for HyBryte™ in CTCL in the United Kingdom
November 7, 2021
Soligenix Announces Publication Demonstrating Enduring Protection of its Thermostable RiVax® Vaccine
November 3, 2021
Soligenix Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of its COVID-19 Vaccine in Non-Human Primates
September 27, 2021
Soligenix to Advance Synthetic Hypericin Development in Psoriasis
September 15, 2021
FDA Grants Soligenix Orphan Drug Designation for the Treatment of T-cell Lymphoma
September 8, 2021
Soligenix Announces Publication Demonstrating Successful Formulation and Heat Stabilization of Filovirus Vaccine Platform for Ebola and Marburg Virus Diseases
August 22, 2021
Soligenix Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine Candidates
August 17, 2021
Soligenix Announces Recent Accomplishments And Second Quarter 2021 Financial Results
August 12, 2021
Soligenix Receives Pediatric Investigational Plan Waiver for HyBryte™ in CTCL from the European Medicines Agency
June 9, 2021
Soligenix Receives $865,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
June 8, 2021
Soligenix Receives Japanese Patent for Improved Production of Synthetic Hypericin Composition
May 19, 2021
Soligenix Announces Recent Accomplishments And First Quarter 2021 Financial Results
May 16, 2021
Soligenix Announces Presentations at Prominent Scientific Conferences
April 12, 2021
Soligenix Receives Conditional FDA Acceptance of Proposed Brand Name HyBryte™ for SGX301 in CTCL
April 6, 2021
Soligenix Announces Recent Accomplishments And Year-End 2020 Financial Results
March 29, 2021
Soligenix to Receive $865,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
March 8, 2021
Soligenix Announces Positive Progress in the Pre-clinical Development of its COVID-19 Vaccine
March 3, 2021
Soligenix is Ready for Commercialization of SGX301 (HyBryte(TM)); FDA Has Approval Process on Fast Track
February 22, 2021
Soligenix Receives Hong Kong Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma
January 31, 2021
Soligenix Announces Strategic Partnership with Daavlin for Supply and Distribution of the SGX301 Companion Light Device in the Treatment of Cutaneous T-Cell Lymphoma
January 6, 2021
Decks in 2021
- Investor Presentation (January 2021)
Investor deck · 71 slides · Jan 26, 2021